High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis

Table 1 Characteristics of the studies included in the meta-analysis

Test	Study, Year	Demographic characteristics				CRC	AN	SCL	Exclusion criteria			Symptoms, %
		N	Age,	Sex,	Area				IBD	OB	AD	AnS	WeL	AbPa	Hem	ChBo	Co	Di	An
			m/md	W%		%	%	%
Mixed cohorts
OC-S	Rozen, 2010[17]	1682	63.7	49.6	IL	1.2	8.9	0	yes	yes	yes	23	NA	NA	0	NA	NA	NA	NA
OC-S	Mc Donald, 2012[20]	280	631	59.6	UK (S)	2.1	NA	21.4	NA	no	no	NA	NA	NA	NA	NA	NA	NA	NA
OC-S	Ou, 2013[21]	694	59.51	55.9	CN	0.4	6.1	NA	yes	yes	no	NA	NA	NA	NA	NA	NA	NA	NA
OC-S	van Turenhout, 2014[18]	3022	59.7	55.0	NL	2.3	12.3	NA	yes	yes	no	44	2.9	11.7	0	18.1	3	4.2	0
OC-S	Symonds, 2016[23]	1381	64.11	50.6	AU	4.8	17.2	NA	no	no	no	34.8	NA	NA	NA	NA	NA	NA	NA
HM-J	Woo, 2005[19]	85	561	52.9	KR	7.1	NA	NA	NA	no	no	49.4	0	15.3	4.7	1.2	0	17.6	4.7
HM-Ja	Auge, 2016[22]	208	631	55.8	ES	1.0	14.0	NA	yes	yes	yes	NA	NA	NA	0	NA	NA	NA	NA
FOB Gold®	Auge, 2018[30]	487	62	51.2	ES	2.5	14.6	NA	no	no	yes	54.2	NA	NA	NA	NA	NA	NA	NA
100% Symptomatic cohorts
OC-S	Mowat, 2016[26]	750	641	54.7	UK (S)	3.7	NA	13.6	no	no	no	100	0.9	11	34.2	42.8	NA	16.8	8.9
OC-S	Rodriguez-Alonso, 2015[25]	1003	NA	46.8	ES	3.0	13.3	23.4	yes	no	no	100	19	36.4	34.2	NA	12.1	23.5	8.8
OC-S	Cubiella, 2014 (DC)[29]	1567	66.9	48.6	ES	13.7	26.7	29.5	no	no	no	100	24.5	43.8	59.9	57.2	14.5	22.2	34.8
OC-S	Cubiella, 2017 (VC)[31]	715	64.4	53.3	ES	9.4	21.1	25.3	no	no	no	100	NA	NA	54	47.9	NA	NA	NA
HM-J	Parente, 2012[24]	280	67	43.9	IT	16.8	47.2	0	yes	no	no	100	11.1	17.9	26.1	23.9	NA	NA	15
HM-Ja	Godber, 2016[27]	484	591	60.1	UK (S)	2.3	NA	9.3	no	no	no	100	1.7	18.8	15.9	39.7	NA	NA	4.8
HM-Ja	Widlack, 2017[28]	430	671	51.0	UK (E)	5.6	NA	NA	no	no	no	100	15.8	30	43	64.2	NA	NA	17.2

¹Age is expressed as median; AbPa: Abdominal pain; AD: Antithrombotic discontinuity; An: Anaemia; AN: advanced neoplasia; AnS: Any symptom; AU: Australia; CN: China; Co: Constipation; CRC: Colorectal cancer; ChBo: Change in bowel habit; DC: Derivation cohort; Di: Diarrhoea; ES: Spain; HM-J: HM-JACK^®; HM-Ja: HM-JACKarc^®; Hem: Haematochezia; IBD: Inflammatory bowel disease; IL: Israel; IT: Italy; KR: South Korea; m: mean; md: median; NA: Non-available; NL: Netherlands; OC-S: OC-Sensor^®; OB: Overt bleeding; SCL: Significant colonic lesion; UK (E): United Kingdom (England); UK (S): United Kingdom (Scotland); VC: Validation cohort; W%: Women%; WeL: Weight loss.